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Summary
Background: Lifestyle interventions are first‐line therapy for non‐alcoholic fatty liver
disease (NAFLD).
Aims: To examine the prevalence of NAFLD among participants of the University of
Michigan Metabolic Fitness (MetFit) Programme and to assess the impact of this
programme on weight, metabolic and liver‐related parameters among patients with
and without NAFLD.
Methods: Adults who completed the programme between 2008 and 2016 were
included. Clinical and laboratory data were collected at enrolment, and at 12 and
24 weeks. NAFLD was defined based on liver biopsy, imaging or clinical diagnosis.
Results: The cohort (N = 403; 253 12‐week, 150 24‐week) consisted primarily of
middle‐aged (median 54 years) white (88%) men (63%) with severe obesity (median
BMI 37.4). 47.6% met criteria for NAFLD. At baseline, NAFLD patients were
younger (52 vs 55 years), had higher weights and more metabolic derangements
(higher fasting insulin and triglyceride, lower high‐density lipoprotein‐cholesterol). At
programme completion, 30% achieved weight reduction ≥5%, 62% resolution of
hypertriglyceridaemia, 33% resolution of low HDL, 27% resolution of impaired fast-
ing glucose and 43% normalisation of alanine aminotransferase. Endpoints were
unaffected by NAFLD. Longer programme duration (OR 6.7, 95% CI 3.6‐12.3) and
white race (OR 3.83, 95% CI 1.04‐1.76) were independent predictors of ≥5% weight
loss.
Conclusions: Nearly half of the patients referred to a structured lifestyle programme
for metabolic syndrome had NAFLD. Although baseline metabolic derangements
were more pronounced among NAFLD patients, the programme was equally effica-
cious in achieving weight loss and resolving metabolic syndrome components. Pro-
gramme duration was the most important predictor of response.
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1 | INTRODUCTION
Obesity has become a worldwide public health crisis given its preva-
lence and multiple associated complications including non‐alcoholic
fatty liver disease (NAFLD). Metabolic syndrome (MetSyn) is highly
correlated with prevalent and incident NAFLD. Approximately 46%
of patients with NAFLD have concomitant MetSyn, and odds of
developing NAFLD are significantly higher among patients with
baseline MetSyn (odds ratios [OR] 4 for men and 11.2 for
women).1,2 The presence of MetSyn has been identified as a predic-
tor for underlying non‐alcoholic steatohepatitis (NASH) among
patients with NAFLD, and the total number of metabolic risk factors
in an individual NAFLD patient is correlated with risk of liver disease
progression.3,4 First‐line treatment for metabolic disease associated
with obesity including NAFLD is lifestyle interventions. From a liver
perspective, multiple studies have demonstrated improvement in
hepatic steatosis and histologic components of NASH among
patients who are able to achieve weight loss.5,6 While 10% reduction
in body weight is generally required to resolve steatosis, inflamma-
tion and fibrosis, a more modest reduction (3%‐5%) has been shown
to decrease steatosis.
In clinical practice, it can be challenging for patients to imple-
ment lifestyle changes. Highly structured lifestyle programmes often
have the highest efficacy for weight loss. One such pro-
gramme is the University of Michigan Metabolic Fitness (MetFit)
Programme. Although many regimented lifestyle programmes were
initially targeted for patients with MetSyn with cardiology and
endocrinology referral bases, these types of programmes represent
potential therapeutic options for patients with NAFLD. The aims of
this study were (a) to evaluate the prevalence of NAFLD among par-
ticipants enrolled in the MetFit Program and to characterise their
patterns of clinical care and (b) to assess the impact of the MetFit
Program among participants with and without NAFLD and to iden-
tify predictors of achieving significant weight loss at programme
completion.
2 | MATERIALS AND METHODS
2.1 | Metabolic Fitness Program
The University of Michigan’s MetFit Program was initially designed
for patients with MetSyn, with detailed description of the pro-
gramme design previously described, but reviewed here.7 MetSyn
was defined as having at least three of the five following variables:
waist circumference of ≥40 inches in men and ≥35 inches in
women, triglycerides (TG) ≥150 mg/dL or treatment targeting TG,
high‐density lipoprotein‐cholesterol (HDL‐C) <40 mg/dL in men and
<50 mg/dL in women, fasting glucose ≥100 mg/dL or diabetes, and
systolic blood pressure ≥130 mm Hg or diastolic blood pressure
≥85 mm Hg or on treatment for hypertension (HTN).8 Indications
for referral have expanded and include NAFLD with or without Met-
Syn. Both a 12‐ and 24‐week programmes are offered.9
The programme was designed to maximise cost‐effective and
time‐efficient real‐world delivery of care and thus utilises an interac-
tive small group design (rather than costly and less efficient one‐on‐
one design).
Sessions occur once per week with each session comprised of a
45‐min educational lecture and a 45‐min supervised exercise session.
Lectures are given in small group settings (roughly 10‐15 patients
per session), with an interactional model that allows individual partic-
ipants to discuss their personal goals and barriers and receive feed-
back from the instructor. Lecture topics include the following: an
orientation lecture on the programme, several lectures on nutritional
topics, several lectures on the impact of stress and behaviour
change, dedicated lectures on exercise and lectures on clinical impact
of metabolic syndrome. Nutritional lecture topics included the
Mediterranean diet, reducing sodium intake, meal planning, portion
control, eating healthily while dining out and interpreting food label-
ling to tailor to a healthy eating plan. The topics for the stress/be-
havioural educational lecture series included emotional barriers to
lifestyle change, strategies to increase awareness of emotional needs
and strategies to decrease the impact of psychosocial stressors on
food choices.
Two exercise physiologists were available during exercise ses-
sions to monitor safety, and educate and encourage participants.
Aerobic exercise intensity was prescribed based on heart rate from
entry graded exercise testing. Exercise intensity was prescribed
based upon the symptom‐limited stress test (treadmill exercise elec-
trocardiogram) and provided as 50%‐75% of predicted maximal heart
rate and perceived exertion as moderately hard. Heart rate targets
were 60%‐85% of heart rate reserve formula (difference between
resting heart rate and maximum predicted heart rate). When graded
exercise testing was not indicated or not available, Borg ratings of
perceived exertion scale were used.10 The Borg rating ranges from 6
(no exertion) to 20 (maximal exertion). Participants were encouraged
to target exertion levels between 11 (fairly light) and 13 (somewhat
hard). Some low‐risk participants were allowed to exercise to intensi-
ties of 15. BMI and central obesity were taken into account for exer-
cise regimen on an individual, as needed basis according to
participant’s report to the exercise physiologists who monitored each
session with alternative exercises provided based on participant‐re-
ported limitations.11,12 Participants were asked to keep a logbook of
aerobic exercise equipment used and total dedicated aerobic and
resistance training each day. Supervised exercise sessions include
aerobic exercise (typically lasting 30‐40 min) using equipment of par-
ticipant choice (treadmill, bike and elliptical), exercise tubes and free‐
weight strength training. The remaining 5‐10 min included stretching
exercises. As a complement to aerobic exercise, participants engaged
in a full‐body strengthening programme (free weight, resistance
bands or combination circuit training targeting all major muscle
groups [legs, chest, back, shoulders, core, biceps and triceps]). In
addition to these supervised sessions, participants were advised to
engage in 150‐300 min of exercise per week consisting of a combi-
nation of moderate/vigorous‐intensity aerobic activity and strength/
resistance training. Each session of exercise was recommended to
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last a minimum of 20 min with a maximum of 60 min per session. In
addition to this moderate‐ to vigorous‐intensity exercise, a full‐body
strengthening programme (free weight, resistance bands or combina-
tion circuit training) was recommended minimum two times weekly
targeting all major muscle groups. Participants had access to the
exercise facility throughout the course of the programme to use for
this purpose.
Dietitians provided nutritional recommendations based on a
Mediterranean diet targeted towards a 12‐week weight loss goal of
5% and 24‐week weight loss goal of 10% of enrolment body weight.
Nutrition data were collected at entry and at completion of the pro-
gramme using a food frequency assessment focusing on a Mediter-
ranean eating pattern. As part of the initial intake evaluation,
personalised energy intake guidelines were calculated by a registered
dietitian, as estimated by the Mifflin‐St Jeor equation based on sex,
age, height, weight and activity level.13 Resting energy equivalent as
determined by the Mifflin‐St Jeor equation was multiplied by an
activity factor of 1.3 for participants who fully participated in the
exercise portion of the programme. For less active participants, an
activity factor of 1.2 was recommended to estimate energy needs.
2.2 | Data collection
Patients complete an initial 1‐h assessment including a history and
physical, and evaluation for barriers to participation. Potential barri-
ers include severe orthopaedic, musculoskeletal or cardiopulmonary
disease, or any other self‐reported barriers that would preclude the
individual from completing components of the programme. A Fram-
ingham risk assessment and the Patient Health Questionnaire‐9
(PHQ‐9) were completed.14 The PHQ‐9 is a 9‐item depression score
with each item rated 0 (not at all) to 3 (nearly every day), with total
scores of 5‐9 representing possible depression, 10‐14 high probabil-
ity of depression and >14 high probability of major depression.
Baseline height, weight, BMI, waist circumference, body composition
percentage (assessed using bioelectrical impedance, Tanita Body
Composition Analyzer Model TBF‐310; Tanita, Arlington Heights, IL,
USA), blood pressure (systolic and diastolic per American Heart
Association standard protocol), glucose, insulin, total cholesterol, TG,
HDL‐C and low‐density lipoprotein‐cholesterol (LDL‐C) were
obtained after a 12‐h fast. Haemoglobin A1c (A1c) and alanine
aminotransferase (ALT) were also obtained. The baseline assessment
was repeated at 12 weeks and then again at 24 weeks for those in
the 24‐week programme. Ethics approval was regulated by the
University of Michigan Health System Institutional Review Board
(HUM0045929), and all participants provided written informed con-
sent.
2.3 | Study inclusion and exclusion criteria
To be included in the primary analysis for this outcome study,
patients had to complete the programme, as defined by attending
>75% of sessions and needed to complete the end of programme
data collection for biometrics and laboratory studies.
2.4 | Definition of NAFLD and outcomes of interest
The diagnosis of NAFLD was ascertained using a natural language
processing programme (University of Michigan EMERSE) and manual
chart review by a hepatologist (MAK).15 A patient was classified as
meeting criteria for NAFLD if they had any of the following in the
absence of significant alcohol use (defined as >14 drinks per week
in men and >7 drinks per week in women; alcohol use was obtained
via self‐report at time of programme enrolment): evidence of steato-
sis or steatohepatitis on liver biopsy; imaging including ultrasound,
computed tomography scan or magnetic resonance imaging noting
hepatic steatosis; a clinical diagnosis code (ICD‐9 or 10) for NAFLD
or NASH; or a combination of the above. We also assessed propor-
tion of patients with NAFLD referred and managed by hepatology
and/or gastroenterology (GI). In addition, we analysed differences in
baseline clinical characteristics and the impact of the programme
between patients with and without NAFLD. Specifically, we investi-
gated percentage weight loss and predictors of weight loss, and
changes in metabolic and liver‐related parameters and change in
depression scores. Insulin resistance was assessed by homeostasis
model assessment‐estimated insulin resistance (HOMA‐IR) among
patients without baseline diabetes and defined as (fasting plasma
insulin × fasting plasma glucose)/22.5, with a value >2.9 indicative of
significant insulin resistance.16
2.5 | Statistical analyses
Descriptive and bivariate analyses were performed to assess baseline
characteristics and impact of the MetFit Program on outcomes of
interest. Chi‐squared tests and Fisher’s exact tests were used for
categorical variables, and t tests were used for continuous variables.
Variables with distributions that deviated from normality were
reported by median and interquartile range (Q1, Q3) and were com-
pared using the Kruskal‐Wallis test. Intention‐to‐treat analysis was
performed for primary outcomes of interest to account for pro-
gramme dropout using multiple variable imputation. Multivariate
analysis was performed to identify predictors of weight loss. Candi-
date covariates were assessed for inclusion into the multivariable
model based on P < 0.10 in the univariate analysis and biologic plau-
sibility. P ≤ 0.05 was considered statistically significant. All analyses
were performed in Stata 14 (StataCorp, College Station, TX).
3 | RESULTS
3.1 | Programme adherence and dropout
Overall completion rate for the MetFit Program was approximately
79% (defined as percentage of participants who complete ≥75% of
sessions). Dropout occurred mostly in the second half of the pro-
gramme. Characteristics of patients who did vs those who did not
complete the programme are detailed in Table S1. Overall, there was
a higher proportion of females among the population of participants
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who did not complete the programme (among participants who did
not complete the programme, 69% were female, whereas 37.5% of
programme completers were female, P < 0.001). There was a similar
proportion of patients with NAFLD who dropped out vs completed
the programme (41.6% vs 47.6%). Participants who dropped out of
the programme had a higher prevalence of central obesity (95.5% vs
88.1%, P = 0.03) but a lower prevalence of hypertriglyceridaemia
(42.2% vs 54.1%, P = 0.04) and low HDL‐C (38.9% vs 57.3%,
P = 0.002). Of note, those who dropped out had higher baseline
PHQ‐9 depression scores (7 vs 5, P = 0.04) and tended to have more
extensive formal educational backgrounds. Baseline characteristics
were otherwise similar between those who dropped out and those
who completed the programme.
3.2 | NAFLD prevalence and care patterns
Within this cohort, 47.6% of patients had evidence of NAFLD. Six-
teen (8.3%) met criteria based on a combination of imaging, clinical
and histologic criteria, 96 (50%) met criteria based on a combination
of imaging and clinical diagnosis, 45 (23.4%) by clinical diagnosis
alone and 35 (18.2%) by imaging criteria alone. Among those meet-
ing diagnostic criteria for NAFLD, only 47 (25%) were managed by
GI/Hepatology for NAFLD. Of note, an additional 31% of patients
with NAFLD had established care with a GI provider for other condi-
tions, but did not have their NAFLD managed or addressed by the
GI provider (Figure 1).
3.3 | Baseline patient characteristics
The baseline characteristics of patients are displayed in Table 1.
Overall, the cohort consisted primarily of middle‐aged (median
54 years) white (88.6%) men (62.5%) with severe obesity (median
BMI 37.4). All five components of MetSyn were present in 19.9%,
four components in 26.9% and three components in 27.9%. NAFLD
patients had higher numbers of components of the MetSyn (median
4 vs 3, P = 0.001). At baseline, patients with NAFLD were younger
(52 vs 55 years, P = 0.004) and more likely to have higher weight
(242 vs 227 lb, P = 0.01) and maximum lifetime weight (250 vs
231 lb, P = 0.008). NAFLD patients also had higher prevalence of
features of the metabolic syndrome and insulin resistance, and
higher prevalence of abnormal ALT. There were no significant differ-
ences in baseline characteristics between participants who com-
pleted the 12‐week vs 24‐week programme aside from a higher
prevalence of baseline HTN in the 24‐week programme (75% vs
57.8%, P = 0.001) (Table S2). Baseline NAFLD Fibrosis Score (NFS),
a noninvasive biomarker of fibrosis in NAFLD, was available in 90
(47%) NAFLD patients. The median NFS was −0.62 (IQR −1.56 to
0.26), with a value of <−1.455 consistent with no‐to‐minimal fibrosis
and a score of >0.675 consistent with advanced fibrosis.17
3.4 | Impact of programme on outcomes of interest
Results of the impact of the MetFit Program are outlined in Table 2.
At 12 weeks, a weight reduction ≥5% was achieved in 23% of par-
ticipants and weight reduction ≥10% in 3.4% of participants. The
programme was efficacious in eliminating components of the Met-
Syn, with resolution of hypertriglyceridaemia (62%) being most com-
mon. The degree of change in triglyceride level was not significantly
different based on use of statin at enrolment (N = 168 on statins).
The distribution of number of components of the MetSyn at
12 weeks was similar among those with and without NAFLD (me-
dian = 3 for both, P = 0.19). Also of note, 36% of patients with
baseline abnormal ALT had normalised ALT and median PHQ‐9 score
improved by 2 points. When the impact of the programme at 12
weeks was stratified by the presence of NAFLD, weight loss and
improvement in metabolic parameters were similar in patients with
and without NAFLD, but patients with NAFLD had a greater
decrease in percentage of body fat (−1.5 vs −0.9, P = 0.009) and a
larger reduction in ALT (−5.5 vs −2 U/L, P = 0.004) (Figure 2). Pre‐
and post‐NFS was available in 36 (19%) NAFLD patients, with a
median change in NFS of −0.21 (IQR −0.73 to 0.77).
In the 24‐week programme, weight reduction ≥5% was achieved
in 53% of participants and weight reduction ≥10% in 16% of partici-
pants. At week 24, median weight loss was 12.5 lb (IQR 5‐20.5), reso-
lution of hyperTG was observed in 35%, low HDL‐C in 34%, impaired
fasting glucose in 30.6% and insulin resistance in 28.7%. The distribu-
tion of number of components of the MetSyn at 24 weeks was simi-
lar among those with and without NAFLD (median = 3 for both,
P = 0.32). Roughly half (54%) of patients with an abnormal ALT had
normalised their ALT. Median PHQ‐9 score remained improved by 2
NAFLD 
NAFLD 
Gl Provider 
No management 
31% 
NAFLD 
GI/Hep management 
25% 
No Gl or Hep provider 
44% 
No 
NAFLD 
52.4% 
F IGURE 1 NAFLD prevalence and care patterns among
participants in Metabolic Fitness Program. Pie chart depicting
percentage of participants in Metabolic Fitness Program with
evidence of underlying non‐alcoholic fatty liver disease (NAFLD) and
distribution of NAFLD patients who received specialty care for their
NAFLD. GI, gastroenterology; Hep, hepatology
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TABLE 1 Baseline patient characteristics according to NAFLD diagnosis
Variables
Median (IQR) or N (%) NAFLD (N = 192) No NAFLD (N = 211) P value
Clinical characteristics
Age, y 52 (45‐59.9) 55 (49‐63) 0.004
Male gender (%) 116 (60.4) 136 (64.5) 0.40
White race (%) 167 (89.3) 182 (87.9) 0.67
Medical comorbidities (%)
CAD 9 (4.7) 15 (7.1) 0.29
Diabetes 65 (33.8) 54 (25.7) 0.07
Metabolic syndrome (%)
Central obesity 179 (93.2) 176 (83.4) 0.002
Hypertension 122 (67.4) 120 (61.2) 0.21
Impaired fasting glucose or DM 133 (69.3) 132 (63.5) 0.22
Hypertriglyceridaemia 116 (60.4) 102 (48.3) 0.01
Low HDL‐C 122 (63.5) 109 (51.6) 0.01
Systolic blood pressure (mm Hg) 120 (110‐130) 120 (110‐136) 0.12
Diastolic blood pressure (mm Hg) 70 (66‐80) 72 (66‐80) 0.43
Duration of programme: 24‐wk (%) 77 (40.1) 73 (34.6) 0.25
Psychosocial assessment
PHQ‐9 depression score 5 (2‐9) 4 (2‐8) 0.15
Employment status (employed) (%) 108 (56.2) 147 (69.6) 0.005
Financial stressors, (yes) (%) 9 (7.1) 11 (5.8) 0.66
Educational background (%)
High school or some post‐high school 55 (28.9) 59 (28.6) 0.46
College graduate 64 (33.7) 59 (28.6)
Post‐graduate/Professional 71 (37.4) 88(42.7)
Anthropometrics
Baseline BMI 38.4 (34.4‐42.6) 36.6 (31.9‐42.7) 0.06
Baseline weight (lb) 242.2 (210.7‐276.3) 227 (191.5‐278) 0.01
Waist circumference (inches) 46.7 (43‐51) 45 (40.5‐50) 0.01
% Body fat 45.6 (39‐49.3) 44.6(39.2‐49.2) 0.74
Max lifetime weight (lb) 250 (220‐290) 231 (200‐285) 0.008
Laboratories
A1c 5.9 (5.6‐6.7) 5.9 (5.6‐6.5) 0.45
Fasting glucose (mg/dL) 108.9 (98.5‐127) 105 (95‐123) 0.15
Fasting insulin (µmol/mL) 21.6 (14.5‐29.8) 16.2 (10.7‐25.1) <0.001
HOMA‐IR (non‐DM) (mU mmol/L2) 5.23 (3.36‐7.79) 3.69 (2.47‐6.26) 0.002
TG (mg/dL) 172.5 (120.5‐273.5) 146 (104‐230) 0.002
LDL‐C (mg/dL) 100 (77‐122) 104 (80‐130) 0.35
HDL‐C (mg/dL) 42 (35‐50) 45 (37‐54) 0.005
ALT (U/L) 41(26‐57) 27 (20‐35) <0.001
Abnormal ALT (>35 U/L) 109 (62.6%) 46 (24.6%) <0.001
Central obesity defined as ≥40 inches in men and ≥35 inches in women.
Hypertension defined as SBP >130 mm Hg, DBP >85 mm Hg or on antihypertensive.
Impaired fasting glucose defined as >100 mg/dL or DM; hyperTG defined as ≥150 mg/dL or on treatment for triglycerides.
Low HDL‐C defined as <40 mg/dL men and <50 mg/dL women.
ALT, alanine aminotransferase; BMI, body mass index; CAD, coronary artery disease; DM, diabetes mellitus; HDL‐C, high‐density lipoprotein‐cholesterol;
HOMA‐IR, homeostasis model assessment‐estimated insulin resistance; LDL‐C, low‐density lipoprotein‐cholesterol; TG, triglycerides.
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TABLE 2 Impact of Metabolic Fitness Program on metabolic, liver‐related and depression parameters stratified by NAFLD status
Change in variable from baseline to end of programme
Median (IQR) or N (%) NAFLD No NAFLD P Value
12‐week N = 192 N = 211
BMI −1.2 (−0.4; −2) −0.9.(−0.3; −1.6) 0.10
Weight (lb) −6.8 (−2; −12.7) −5.5 (−1.6; −10) 0.08
≥5% Reduction 48 (25%) 44 (20.9%) 0.32
≥10% Reduction 6 (3.1%) 8 (3.8%) 0.70
Waist circumference (in) −1.5 (0; −3) −1.3 (0; −2.7) 0.48
% Body fat −1.5 (−0.2; −2.9) −0.9 (0; −2.2) 0.009
Features of metabolic syndrome (%)
Loss of central obesity 11 (6.1) 18 (10.3) 0.15
Resolution of hypertension 9 (7.6) 7 (5.8) 0.59
Resolution of indicators of insulin resistance
(reduction in fasting glucose to ≤100mg/dL)
31 (24.1) 28 (22.5) 0.73
Resolution of hypertriglyceridaemia 65 (56) 68 (68) 0.07
Resolution of low HDL 44 (36.1) 35 (32.7) 0.59
Systolic blood pressure (mm Hg) −4 (−12; +5) −6 (−18; +2) 0.29
Diastolic blood pressure (mm Hg) −2 (−8; +4) −3 (−10; +2) 0.35
A1c −0.2 (0; −0.5) −0.1 (0; −0.3) 0.15
Fasting glucose (mg/dL) −5 (+4; −14) −3 (+3; −11) 0.21
Insulin (µmol/mL) −2.4 (+2.4; −9.2) −0.8 (+2.4; −6.3) 0.09
HOMA‐IR (non‐DM), (mU mmol/L2) −0.73 (+0.44; −2.44) −0.16 (+0.49; −1.49) 0.17
TG (mg/dL) −32.5 (+10; −93) −22 (+3; −57) 0.28
LDL‐C (mg/dL) 0 (+10; −11) −3 (+9; −14) 0.18
HDL‐C (mg/dL) −1 (+2; −4) 0 (+3; −4) 0.69
ALT (U/L) −5 5 (+2; −16) −2 (+3; −7) 0.004
Normalisation of ALT (<35) 30/102 (29.4%) 21/39 (53.8%) 0.007
PHQ‐9 score −2 (0;−4) −2 (0;−4) 0.69
24‐wk N = 77 N = 73
BMI −2.2 (−0.6; −3.4) −1.9 (−0.8; −3.0) 0.75
Weight (lb) (%) −13.5 (−3.5; −22.5) −11.7 (−5.5; −18.5) 0.72
≥5% Reduction 43(55.8) 36 (49.3) 0.42
≥10% Reduction 12 (15.6) 12 (16.4) 0.88
Waist circumference −2.9 (−0.7; −4.5) −2.5 (−0.5; −4) 0.59
% Body fat −1.9 (−0.3; −4.1) −1.9 (−0.7; −3.4) 0.94
Features of metabolic syndrome (%)
Loss of central obesity 11 (15.1) 10 (16.4) 0.83
Resolution of hypertension 6 (10.7) 3 (6.3) 0.44
Resolution of indicators of insulin resistance
(reduction in fasting glucose to ≤100mg/dL)
13 (27.1) 17 (34) 0.46
Resolution of hypertriglyceridaemia 18 (35.9) 14 (35.9) 0.89
Resolution of low HDL 15 (30.6) 15 (37.5) 0.49
Systolic blood pressure (mm Hg) −3 (−18; +6) −8 (−18; +6) 0.42
Diastolic blood pressure (mm Hg) −2 (−12; +6) −2 (−14; +4) 0.66
A1c (%) −0.2 (0; −0.5) −0.1 (0; −0.6) 0.88
Fasting glucose (mg/dL) −6 (+4; −17) −4 (+3; −11) 0.58
Insulin (µmol/mL) −2.5(−0.5; −9.1) −4.9 (−1.5; −9.8) 0.06
HOMA‐IR (non‐DM) (mU mmol/L2) −0.72 (+0.35; −2.21) −1.38 (−0.30; −3.15) 0.06
(Continues)
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points compared to baseline. Weight loss and improvement in meta-
bolic parameters were similar in patients with and without NAFLD,
but patients with NAFLD were noted to have a greater decrease in
TG (−45 mg/dL vs −23 mg/dL, P = 0.05) and a larger reduction in
ALT (−11 U/L vs −3 U/L, P = 0.003) (Figure 2).
Intention‐to‐treat analysis to evaluate impact of outcomes at
week 12 demonstrated similar overall trends in change in weight,
fasting glucose, TG, HDL and ALT (Table S3). There were more pro-
nounced reductions in weight and resolution of low HDL among par-
ticipants with NAFLD in this subanalysis.
TABLE 2 (Continued)
Change in variable from baseline to end of programme
Median (IQR) or N (%) NAFLD No NAFLD P Value
TG (mg/dL) −45 (−9; −113) −23 (+3; −58) 0.05
LDL‐C (mg/dL) 0 (+13; −18) −4 (+6; −13.5) 0.34
HDL‐C (mg/dL) +1 (+6; −4) 0 (+3; −3) 0.51
ALT (U/L) −11 (−0.5; −28.5) −3 (+1; −9) 0.003
Normalisation of ALT (<35) 22/46 (47.8%) 9/11 (81.8%) 0.04
PHQ‐9 score −2 (0;−5) −2 (0;−5) 0.79
Central obesity defined as ≥40 inches in men and ≥35 inches in women; hypertension defined as SBP >130 mm Hg, DBP >85 mm Hg or on antihyper-
tensive. Impaired fasting glucose defined as >100 mg/dL or DM; hyperTG defined as ≥150 mg/dL or on treatment for triglycerides; low HDL‐C defined
as <40 mg/dL men and <50 mg/dL women.
ALT, alanine aminotransferase; BMI, body mass index; HDL‐C, high‐density lipoprotein‐cholesterol; HOMA‐IR, homeostasis model assessment‐estimated
insulin resistance; LDL‐C, low‐density lipoprotein‐cholesterol; TG, triglycerides.
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3.5 | Predictors of weight loss
Characteristics of patients who did and those who did not achieve
≥5% weight reduction by programme completion are displayed in
Table 3. Those with ≥5% weight reduction were more likely to be
women and to be white, and had a higher baseline weight (241 lb vs
235.5 lb, P = 0.05) and a higher median ALT (35 vs 30 IU/L,
P = 0.03) compared to those with <5% weight reduction. Likelihood
of achieving ≥5% weight reduction was similar in patients with or
without NAFLD. The most striking variable associated with achieving
≥5% weight reduction was duration of programme participation. As
expected, individuals who were able to achieve ≥5% weight loss
were more likely to have improvement in metabolic parameters
including resolution of central obesity (19.3% vs 6.9%, P = 0.001)
and impaired fasting glucose (38.4% vs 23.2%, P = 0.01), and more
pronounced reductions in A1c, fasting glucose, fasting insulin, insulin
resistance and TG. They also had more pronounced reduction in
ALT.
A subanalysis of individuals with and without ≥10% weight loss
noted that participants with a higher maximum weight (P = 0.04) and
those who completed the 24‐week programme were significantly
more likely to achieve ≥10% weight loss (82.7% vs 33.7%,
P < 0.001). Participants who achieved ≥10% weight loss had higher
rates of resolution of central obesity (26.9% vs 9.5%, P = 0.006),
impaired fasting glucose (76.5% vs 24%, P < 0.001), insulin resis-
tance (70.6% vs 14.6%, P < 0.001) and more pronounced improve-
ments in A1c, TG and ALT (Table S4).
Multivariate analysis of predictors of ≥5% weight loss is demon-
strated in Table S5. Duration of programme participation was the
strongest independent predictor (odds ratio [OR] 6.79 95% CI 3.7‐
12.4, P < 0.001). White race was the only other significant variable
with an OR of 3.83 (95% CI 1.04‐14.03, P = 0.04). Additional analy-
sis of characteristics based on race was performed to evaluate
whether any other covariates may be mediators of this relationship
(Table S6). Participants of white race (N = 349, 87%) were older (55
vs 48.8), had less college/post‐graduate education (68.6% vs 88.6%),
a higher prevalence of HTN (66.5% vs 48.8%), larger waist circum-
ference (46 vs 43 in), higher percentage body fat (45.5% vs 43%)
and higher TG (160 vs 123) at baseline compared to participants of
other races.
4 | DISCUSSION
Non‐alcoholic fatty liver disease is one of the most common forms
of chronic liver disease, affecting 25%‐30% of the United States’
population.18,19 Weight loss through lifestyle changes is a proven
therapy for this highly prevalent disease. Unfortunately, implementa-
tion of lifestyle changes and achievement of sustained weight loss
remains challenging for many patients. Structured lifestyle pro-
grammes often result in higher rates of weight loss due to regi-
mented recommendations and follow‐up. These types of
programmes have long been designed and targeted for patients with
cardiac or endocrine disease, but due to the underlying metabolic
nature of NAFLD, lifestyle programmes are also relevant for patients
with NAFLD.
The results of our study mirror findings of other investigations of
prevalence of NAFLD among patients with metabolic disease.1,20 In
this cohort, just under half of the patients had evidence of NAFLD.
This is likely an underestimate as not all patients had undergone
testing to evaluate for possible NAFLD. Another finding of note is
that only one quarter of patients with NAFLD were referred to and
managed by a GI or liver specialist for their NAFLD. Also of note, an
additional one third of NAFLD patients were under the care of a GI
provider for other conditions (eg, acid reflux and diarrhoea), but they
did not receive care related to NAFLD. Taken together, this pattern
of care reflects low disease awareness among patients and providers,
even in the face of multiple metabolic risk factors.21,22 These care
patterns also reflect perceptions regarding the clinical significance
and treatment options for NAFLD held by many providers.23 This
low rate of referral to GI/Hepatology is in line with data from prior
studies where 71% of providers reported that they did not refer
patients with suspected NAFLD to GI/Hepatology.24,25 These defi-
ciencies in the care cascade represent key areas for improvement in
order to optimise long‐term outcomes for this burgeoning patient
population. It is important to note the potential implications of low
rates of referral including the potential to make accurate diagnoses
of NAFLD and NASH and risk stratification for stage of liver disease.
Although routine screening among high‐risk patients is not currently
recommended due to uncertainties around diagnostic approaches
and cost‐effectiveness of screening, the role for screening will con-
tinue to evolve as additional therapeutic options and predictive mod-
els for advanced or rapidly progressive NAFLD become available.26–
28
We also highlighted the differences in baseline characteristics of
patients with and without NAFLD among patients with the MetSyn.
Patients with NAFLD were younger and more likely to have higher
baseline weight, maximum lifetime weight and central obesity. They
were also more likely to have hyperTG, low HDL‐C and higher
HOMA‐IR. These unique characteristics underscore the importance
of central adiposity and insulin resistance in NAFLD as metabolic
health has been independently associated with risk of NASH and sig-
nificant fibrosis.29,30 Despite having more pronounced metabolic
derangements at baseline, NAFLD patients were equally likely to
respond to the lifestyle programme. This finding is of note given
concerns that NAFLD patients may have different uptake and
response rates to lifestyle changes stemming from different baseline
motivation to change and lower confidence to exercise.31–33 In this
study, we found that duration of programme participation was the
strongest predictor of weight loss. In our prior studies, we had
demonstrated that the number of MetS criteria was correlated with
the number of programme sessions attended (OR 2.27), highlighting
a potential predictor of programme completion that can be used to
help target interventions to increase adherence among partici-
pants.34 Although race was an independent predictor of weight loss,
we are limited in our ability to draw conclusions from this finding
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TABLE 3 Baseline characteristics and change in metabolic, liver‐related and depression parameters stratified by achievement of ≥5% weight
loss
Variable
Median (IQR) or N (%) ≥ 5% Weight loss (N = 121) <5% Weight loss (N = 282) P value
Baseline characteristics
Age 56 (48.5‐62.5) 53.7 (46‐61) 0.19
Male gender (%) 67 (55.4) 186 (65.6) 0.05
White race (%) 112 (93.3) 237 (86.5) 0.05
Medical comorbidities (%)
CAD 8 (6.6) 16 (5.6) 0.70
Diabetes 33 (27.5) 85 (30) 0.54
Metabolic syndrome components (%)
Central obesity 110 (90.9) 245 (86.9) 0.25
Hypertension 76 (67.8) 166 (62.6) 0.33
Impaired fasting glucose or DM 75 (61.9) 192 (68.1) 0.23
Hypertriglyceridaemia 68 (56.2) 150 (53.2) 0.57
Low HDL‐C 71 (58.6) 160 (56.8) 0.72
NAFLD (%) 63 (52.1) 129 (45.7) 0.24
PHQ‐9 depression score 4 (2‐8) 5 (2‐8) 0.11
Programme duration: 24‐wk (%) 79 (65.3) 71 (25.2) <0.001
Baseline psychosocial assessment
Financial stressors, yes (%) 3 (3.3) 17 (7.6) 0.15
Educational background (%)
High school or some post‐high school 34 (28.8) 80 (28.8) 0.98
College graduate 36 (30.5) 87 (31.3)
Post‐graduate/professional 48 (40.6) 111 (39.9)
Baseline anthropometrics
Baseline BMI 38.5 (33.7‐41.9) 36.9 (32.6‐42.9) 0.52
Baseline weight, lb 241 (210‐284) 235.5 (200.5‐276) 0.05
Waist circumference, in 46.3 (43‐50) 46 (41‐50.5) 0.22
% Body fat 44.5 (37.4‐49) 45.3 (39.8‐49.5) 0.28
Max lifetime weight, lb 250 (219‐300) 241 (205‐285) 0.06
Baseline laboratories
A1c 5.9 (5.6‐6.5) 5.9 (5.6‐6.5) 0.39
HOMA‐IR (non‐DM) (mU mmol/L2) 4.73 (2.89‐7.09) 4.44 (2.76‐6.81) 0.67
TG (mg/dL) 161 (112‐268) 157 (111‐238) 0.45
LDL‐C (mg/dL) 96 (77‐121) 103 (80‐128) 0.18
HDL‐C (mg/dL) 43 (36‐49) 43.5 (36‐52) 0.74
ALT (U/L) 35 (23‐53) 30 (22‐42) 0.03
Abnormal ALT (>35 U/L) (%) 52 (49.5) 103 (40.2) 0.11
Change in clinical parameters
Features of metabolic syndrome (%)
Loss of central obesity 21 (19.3) 17 (6.9) 0.001
Resolution of hypertension 6 (8.1) 13 (7.9) 0.97
Resolution of indicators of insulin resistance
(reduction in fasting glucose to ≤100mg/dL)
28 (38.4) 42 (23.2) 0.01
Resolution of hypertriglyceridaemia 37 (55.2) 95 (65.1) 0.16
Resolution of low HDL 28 (39.4) 49 (31.2) 0.22
A1c −0.2 (−0.1; −0.8) −0.1 (+0.1; −0.3) <0.001
(Continues)
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given that 88% of participants were of white race. However, this
finding has been previously described in the literature with higher
rates of success in weight loss in part attributed to differences in
basal metabolic rates.35–37 On subanalysis, those of non‐white race
appeared to have more favourable baseline metabolic characteristics
(younger age, lower baseline waist circumference, percentage body
fat and TG). These racial differences for propensity for weight loss
are particularly interesting given the variable prevalence rates of
NAFLD across different races and ethnicities.38,39
There are several limitations to note for our study. First, the
diagnosis of NAFLD was made based on chart review and natural
language processing and is inherently prone to both over‐ and
underclassification. Second, our patient population is relatively
homogenous and thus the results of this study may not generalise to
the larger population of patients with NAFLD. Additionally, our cur-
rent programme design does not include structured, prospective fol-
low‐up post‐programme completion, so we are unable to speak to
the durability of the benefits achieved through this programme. Our
recent retrospective study of participants with follow‐up data avail-
able in our health system (N = 225) demonstrated that at 12 months
after programme completion, while the majority of parameters were
still improved compared to baseline, only change in LDL‐C remained
significantly improved compared to end of 12‐week programme.40
These findings echo those reported in follow‐up after completion of
most structured lifestyle intervention programmes where participants
regain weight over time, but the majority are able to remain below
programme entry weight.41–43 While programme design varies widely
in terms of duration and intensity of follow‐up, most programmes
are designed for 3‐6 months and do not incorporate post‐programme
follow‐up. Overall, these findings of difficulty with maintenance of
benefit post‐programme completion highlight the primary limitation
of these interventions and the need for maintenance interventions
over the long term.44 Incorporation of follow‐up touch points using
eHealth modalities has been shown to be a potentially beneficial
mechanism to sustain improvements over time, and as such warrant
further investigation.45 A strength of our study in terms of NAFLD
prevalence assessment was our ability to rule out heavy alcohol use
in this cohort as an alcohol use assessment was performed as a stan-
dard part of enrolment into the programme. Another key strength is
the detailed clinical, anthropometric and HRQOL assessments at
baseline and programme completion that enabled us to conduct in‐
depth analysis of the different types of benefits of fitness pro-
grammes in patients with MetSyn and NAFLD. While weight loss
and improvements in metabolic parameters have been reported in
many lifestyle intervention programmes, ours is one of the few
demonstrating a decrease in PHQ‐9, a measure of depression.
In conclusion, we demonstrated that roughly one‐half of patients
participating in a structured lifestyle intervention programme pre-
dominantly referred because of cardiovascular or endocrine diseases
had evidence of underlying NAFLD, but only a quarter of the
NAFLD patients were being specifically managed for their NAFLD
by a specialist. We also found that metabolic derangements were
more pronounced at baseline in NAFLD patients, but despite this
NAFLD patients were equally responsive to the lifestyle programme.
As expected, we found that a longer duration of programme partici-
pation was the most important predictor of significant weight loss.
Our data can be used to help counsel NAFLD patients regarding
expectations and timeline for lifestyle interventions to achieve target
weight loss. It can also provide a framework for the design of future
lifestyle intervention programmes targeted specifically for NAFLD
patients. Future prospective assessment of for baseline NAFLD with
detailed liver‐specific endpoints including elastography would add to
our knowledge of the disease‐specific benefits of structured lifestyle
programmes for this population.
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TABLE 3 (Continued)
Variable
Median (IQR) or N (%) ≥ 5% Weight loss (N = 121) <5% Weight loss (N = 282) P value
Fasting glucose (mg/dL) −6 (+3; −16) −3 (+4; −12) 0.03
Fasting insulin (µmol/mL) −5.9 (−0.7; −10.5) −1.1 (+2.6; −5.8) <0.001
HOMA‐IR (non‐DM) (mU mmol/L2) −1.49 (−0.20; −3.01) −0.27 (+0.64; −1.38) <0.001
TG (mg/dL) −38 (−13; −119) −16 (+18; −52) <0.001
HDL‐C (mg/dL) 0 (+4; −3) 1 (+3; −4) 0.30
LDL‐C (mg/dL) −3 (+10; −17) −1 (+11; −13) 0.26
ALT (U/L) −10 (−3; −27) −2 (+4; −10) <0.001
Normalisation of ALT (<35 IU/L) (%) 27 (57.4) 34 (35.7) 0.01
Change in PHQ‐9 score 2 (0; 5) 2(0; 4) 0.19
Central obesity defined as ≥40 inches in men and ≥35 inches in women. Hypertension defined as SBP >130 mm Hg, DBP >85 mm Hg or on antihyper-
tensive. Impaired fasting glucose defined as >100 mg/dL or DM; hyperTG defined as ≥150 mg/dL or on treatment for triglycerides. Low HDL‐C defined
as <40 mg/dL men and <50 mg/dL women.
ALT, alanine aminotransferase; BMI, body mass index; HDL‐C, high‐density lipoprotein‐cholesterol; HOMA‐IR, homeostasis model assessment‐estimated
insulin resistance; LDL‐C, low‐density lipoprotein‐cholesterol; TG, triglycerides.
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